Toxicity of Per- and Polyfluoroalkyl Substances to Aquatic Invertebrates, Planktons, and Microorganisms.

Per- and polyfluoroalkyl substances (PFASs), recognized worldwide as emerging pollutants, may pose a substantial threat to human health and our environment due to their stability, high concentrations, wide distribution, and easy accumulation. Ever since perfluorooctane sulfonate and perfluorooctanoic acid were recognized by the Stockholm Convention on Persistent Organic Pollutants, the public has become increasingly concerned about potential contamination and the environmental risks associated with PFASs. Ubiquitous PFAS contamination of drinking water, groundwater, surface water, and sediment has been detected, especially in areas with rapid industrial and economic development. Its accumulation in living organisms and foods has accentuated the importance of investigations into aquatic organisms at the bottom of the food chain, as the stability and integrity of the food web as well as the population quantity and structure of the aquatic ecosystem may be affected. This review provides a comprehensive summary of the toxic and toxicity-related effects of PFASs on aquatic plankton, aquatic invertebrates and microorganisms, the characteristics of different target aquatic organisms in toxicity investigations, and a feasibility evaluation of PFAS substitutes to provide valuable suggestions for further utilization and regulation of PFASs and their substitutes.

The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients.

PURPOSE: To retrospectively analyze the efficacy and toxicity of epirubicin plus cyclophosphamide followed by docetaxel (EC-D) and epirubicin plus cyclophosphamide followed by paclitaxel (EC-P) efficacy as neoadjuvant chemotherapy regiments by pathological complete response (pCR) in this study. METHODS: In total, 455 patients diagnosed with breast cancer who received NAC from January 2014 to January 2019 were enrolled. Of which, 109 patients received EC-D (E: 90, C: 600, D: 80, all in mg/m2) and 346 were treated with EC-P (E: 90, C: 600, D: 175, all in mg/m2). Efficacy of NAC regimens was evaluated by pCR, and the toxicity was studied. Chi-squared test was used at p=0.05. RESULTS: In EC-D, 11 patients received ypT0/isN0, and 6 of them got ypT0N0. Analogously, 67 patients receiving received EC-P obtained ypT0/isN0, and 43 people of them acquired ypT0N0. The rate of pCR in EC-P was higher than EC-D. Patients with ER (-), PR (-), Her-2 (+) and high Ki-67 index were easier to were more likely to acquire pCR. Two pCRs were described, the pCR of NAC differed according to the definition. In terms of side effects, there was no significant difference in platelet and urea, but the decrease of hemoglobin and creatinine levels after EC-P treatment was more significant than that after EC-D treatment. CONCLUSION: The efficacy of EC-P is better than EC-D if pCR is to be determined as a surrogate end-point for prognosis. The patients with anemia or renal insufficiency who need to receive NAC should choose EC-D.

Effects of Chemotherapy on Serum Lipids in Chinese Postoperative Breast Cancer Patients.

PURPOSE: Chemotherapy is a comprehensive therapy for breast cancer; nevertheless, its associated adverse effects are drawing increasing attention with the continuous improvement of the efficacy. The changes in serum lipids of breast cancer patients caused by chemotherapy have been reported by previous studies, whereby the former increase the incidence rate of cardiovascular disorders. However, the variations in the changes of serum lipids with different chemotherapy regimens have seldom been reported. METHODS: From January 2011 to December 2017, 1740 breast cancer patients treated with chemotherapy were recruited at the First Affiliated Hospital of Nanjing Medical University. The chemotherapy regimens included anthracycline-based, taxane-based, and anthracycline-plus-taxane-based regimens, dose-dense and standard-interval regimens. Lipid profiles that contained TG (triglyceride), TC (total cholesterol), HDL-C (high-density lipoprotein cholesterol), LDL-C (low-density lipoprotein cholesterol) and Lpa (lipoprotein a) levels were collected prior to the first, second and last cycles of chemotherapy. The changes of serum lipids with the same or different chemotherapy regimens were analyzed and compared. RESULTS: It was observed that the levels of TG, TC, LDL-C and Lpa increased significantly while that of HDL-C decreased after adjuvant chemotherapy in breast cancer patients (P<0.05). Besides, dose-dense regimens had more influence in TG and HDL-C and less influence in TC and LDL-C than standard-interval regimens. HDL-C was more sensitive to anthracycline-based regimens than taxane-based regimens. The level of TG with anthracycline-plus-taxane-based regimens was higher than that with only anthracycline-based or taxane-based regimens, and the level of HDL-C with anthracycline-plus-taxane-based regimen showed lower than that with taxane-based regimen. CONCLUSION: In summary, this study proposed that dyslipidemia was strongly associated with chemotherapy in Chinese breast cancer patients after operative treatment. Furthermore, the changes in levels of serum lipids varied among patients with different chemotherapy regimens and taxane had less effect on dyslipidemia than anthracycline.

Cell damage caused by ultraviolet B radiation in the desert cyanobacterium Phormidium tenue and its recovery process.

Phormidium tenue, a cyanobacterium that grows in the topsoil of biological soil crusts (BSCs), has the highest recovery rate among desert crust cyanobacteria after exposure to ultraviolet B (UV-B) radiation. However, the mechanism underlying its recovery process is unclear. To address this issue, we measured chlorophyll a fluorescence, generation of reactive oxygen species (ROS), lipid peroxidation, and repair of DNA breakage in P. tenue following exposure to UV-B. We found that UV-B radiation at all doses tested reduced photosynthesis and induced cell damage in P. tenue. However, P. tenue responded to UV-B radiation by rapidly reducing photosynthetic activity, which protects the cell by leaking less ROS. Antioxidant enzymes, DNA damage repair systems, and UV absorbing pigments were then induced to mitigate the damage caused by UV-B radiation. The addition of exogenous antioxidant chemicals ascorbate and N-acetylcysteine also mitigated the harmful effects caused by UV-B radiation and enhanced the recovery process. These chemicals could aid in the resistance of P. tenue to the exposure of intense UV-B radiation in desertified areas when inoculated onto the sand surface to form artificial algal crusts.

Performance of an Ultraviolet Mutagenetic Polyphosphate-Accumulating Bacterium PZ2 and Its Application for Wastewater Treatment in a Newly Designed Constructed Wetland.

Total phosphorus (TP) removal performance and application for wastewater treatment of polyphosphate-accumulating bacteria (PAB) in constructed wetlands (CWs) were investigated. In this study, a novel isolated ultraviolet (UV) mutant PZ2 with phosphate-accumulating ability was screened from domestic wastewater and identified as Pseudomonas putida by 16S ribosomal DNA (rDNA) sequencing analysis. The TP removal performance of PZ2 in the synthetic wastewater reached the highest of 93.95 % within 45 h. Two vertical subsurface flow CWs planted with two aquatic macrophytes Canna indica and Acorus calamus were newly designed. After inoculating PZ2 into two CWs within 45 h, the average chemical oxygen demand (COD), TP, and ammonia-nitrogen (NH3-N) removal efficiencies reached 68.50, 60.22, and 66.81 %, respectively. Vegetation type and filter size significantly influenced the TP removal capability of PZ2 in CWs. Meanwhile, considerable qualitative differences were found in the pollutant removal efficiencies of PZ2 with and without CWs in synthetic wastewater. These results could also indicate potential applications of the UV mutagenesis in PAB isolation and the newly designed CWs in wastewater treatments.